Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 11 |
| List of Tables | 11 | 1 |
| List of Figures | 12 | 1 |
| Introduction | 13 | 1 |
| Global Markets Direct Report Coverage | 13 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview | 14 | 1 |
| Therapeutics Development | 15 | 2 |
| Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview | 15 | 1 |
| Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Comparative Analysis | 16 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics under Development by Companies | 17 | 3 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Products Glance | 21 | 4 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Unknown Stage Products | 24 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Products under Development by Companies | 25 | 4 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Products under Investigation by Universities/Institutes | 29 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Companies Involved in Therapeutics Development | 30 | 31 |
| Aeolus Pharmaceuticals, Inc. | 30 | 1 |
| Angion Biomedica Corp. | 31 | 1 |
| Atox Bio Ltd. | 32 | 1 |
| BCN Biosciences L.L.C. | 33 | 1 |
| Bolder Biotechnology, Inc. | 34 | 1 |
| Cellerant Therapeutics, Inc. | 35 | 1 |
| Cellphire, Inc. | 36 | 1 |
| Chrysalis BioTherapeutics, Inc. | 37 | 1 |
| Cleveland BioLabs, Inc. | 38 | 1 |
| Cumberland Pharmaceuticals, Inc. | 39 | 1 |
| Diffusion Pharmaceuticals Inc. | 40 | 1 |
| GNI Group Ltd. | 41 | 1 |
| Humanetics Corporation | 42 | 1 |
| INSYS Therapeutics, Inc. | 43 | 1 |
| Meabco A/S | 44 | 1 |
| Neumedicines Inc. | 45 | 1 |
| Nohla Therapeutics Inc. | 46 | 1 |
| Onconova Therapeutics, Inc. | 47 | 1 |
| Original BioMedicals Co. Ltd. | 48 | 1 |
| PharmaIN Corporation | 49 | 1 |
| Pluristem Therapeutics Inc. | 50 | 1 |
| RDD Pharma Ltd. | 51 | 1 |
| Reata Pharmaceuticals, Inc. | 52 | 1 |
| RedHill Biopharma Ltd. | 53 | 1 |
| RxBio, Inc. | 54 | 1 |
| SK Chemicals Co., Ltd. | 55 | 1 |
| Soligenix, Inc. | 56 | 1 |
| Stemedica Cell Technologies, Inc. | 57 | 1 |
| Terapio Corporation | 58 | 1 |
| Tonix Pharmaceuticals Holding Corp. | 59 | 1 |
| Vida Therapeutics Inc. | 60 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics Assessment | 61 | 11 |
| Assessment by Monotherapy Products | 61 | 1 |
| Assessment by Target | 62 | 3 |
| Assessment by Mechanism of Action | 65 | 3 |
| Assessment by Route of Administration | 68 | 2 |
| Assessment by Molecule Type | 70 | 2 |
| Drug Profiles | 72 | 123 |
| A-02 Drug Profile | 72 | 1 |
| AB-103 Drug Profile | 73 | 3 |
| ABC-294640 Drug Profile | 76 | 5 |
| AEOL-10150 Drug Profile | 81 | 9 |
| AEOL-10171 Drug Profile | 90 | 1 |
| amifostine Drug Profile | 91 | 1 |
| Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis Drug Profile | 92 | 1 |
| AVMOC-001 Drug Profile | 93 | 1 |
| BB-3 Drug Profile | 94 | 3 |
| BBT-007 Drug Profile | 97 | 1 |
| BBT-015 Drug Profile | 98 | 1 |
| BBT-018 Drug Profile | 99 | 1 |
| BBT-059 Drug Profile | 100 | 1 |
| BCN-057 Drug Profile | 101 | 1 |
| BIO-300 Drug Profile | 102 | 3 |
| BMX-001 Drug Profile | 105 | 1 |
| BPC-2 Drug Profile | 106 | 1 |
| C-2E2 Drug Profile | 107 | 1 |
| C-2E5 Drug Profile | 108 | 1 |
| Cell Therapy for Acute Radiation Syndrome Drug Profile | 109 | 1 |
| cerium oxide Drug Profile | 110 | 1 |
| CLT-009 Drug Profile | 111 | 1 |
| Des-Asp Angiotensin 1 Drug Profile | 112 | 1 |
| Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis Drug Profile | 113 | 1 |
| entolimod Drug Profile | 114 | 7 |
| EWA-001 Drug Profile | 121 | 1 |
| HSJ-0017 Drug Profile | 122 | 1 |
| JP4-039 Drug Profile | 123 | 2 |
| LGM-2605 Drug Profile | 125 | 1 |
| m-2A2 Drug Profile | 126 | 1 |
| molgramostim Drug Profile | 127 | 1 |
| monosodium luminol Drug Profile | 128 | 2 |
| NMIL-121 Drug Profile | 130 | 3 |
| omaveloxolone Drug Profile | 133 | 3 |
| ondansetron hydrochloride Drug Profile | 136 | 1 |
| ondansetron hydrochloride CR Drug Profile | 137 | 5 |
| Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis Drug Profile | 142 | 1 |
| pirfenidone Drug Profile | 143 | 2 |
| PLXR-18 Drug Profile | 145 | 6 |
| RDD-2007 Drug Profile | 151 | 1 |
| recilisib sodium Drug Profile | 152 | 2 |
| Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity Drug Profile | 154 | 1 |
| Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis Drug Profile | 155 | 1 |
| Recombinant Protein to Activate FGF-4 for Radiation Injury Drug Profile | 156 | 1 |
| Recombinant Protein to Activate FGF-7 for Radiation Injury Drug Profile | 157 | 1 |
| RES-529 Drug Profile | 158 | 4 |
| RP-239X Drug Profile | 162 | 1 |
| rusalatide acetate Drug Profile | 163 | 3 |
| Rx-100 Drug Profile | 166 | 2 |
| SGX-201 Drug Profile | 168 | 1 |
| SGX-202 Drug Profile | 169 | 3 |
| SKI-2162 Drug Profile | 172 | 1 |
| Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury Drug Profile | 173 | 1 |
| Small Molecules for Radiation and Chemical Toxicity Drug Profile | 174 | 1 |
| Small Molecules for Radiation Toxicity Drug Profile | 175 | 1 |
| Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology Drug Profile | 176 | 1 |
| ST-266 Drug Profile | 177 | 2 |
| ST-7 Drug Profile | 179 | 1 |
| Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile | 180 | 6 |
| SY-303A Drug Profile | 186 | 1 |
| SY-513 Drug Profile | 187 | 1 |
| SYGN-305 Drug Profile | 188 | 1 |
| SYGN-399 Drug Profile | 189 | 1 |
| Thrombosomes Drug Profile | 190 | 1 |
| TPO-7630 Drug Profile | 191 | 1 |
| TPO-7640 Drug Profile | 192 | 1 |
| VEDA-1209 Drug Profile | 193 | 1 |
| VTI-1000 Series Drug Profile | 194 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Dormant Projects | 195 | 5 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Discontinued Products | 200 | 1 |
| Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Product Development Milestones | 201 | 10 |
| Featured News &Press Releases | 201 | 1 |
| Aug 10, 2016: Humanetics Receives Federal Grant to Further Develop Radiation Countermeasure | 201 | 1 |
| Jul 25, 2016: Soligenix Receives Additional BARDA and NIAID Funding to Advance Development of OrbeShield in GI ARS | 201 | 1 |
| Jul 20, 2016: Pluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health s NIAID | 202 | 1 |
| May 02, 2016: Chrysalis BioTherapeutics receives $3 million grant for nuclear countermeasure development | 202 | 1 |
| Mar 16, 2016: Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure | 203 | 1 |
| Feb 22, 2016: Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016 | 203 | 1 |
| Feb 16, 2016: National Institutes of Health s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem s PLX-R18 in the Treatment of Acute Radiation Syndrome | 204 | 1 |
| Jan 21, 2016: Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure | 205 | 1 |
| Sep 21, 2015: Department of Defense Grants Cleveland BioLabs Second Award for Advanced Development of Entolimod as a Medical Radiation Countermeasure | 205 | 1 |
| Sep 21, 2015: Pluristem and NIAID Met With U.S. FDA and Agreed on Development Plan for Initiation of Pivotal Study of PLX-R18 in the Treatment of Acute Radiation Syndrome | 206 | 1 |
| Sep 16, 2015: Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation | 206 | 1 |
| Sep 02, 2015: Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure | 207 | 1 |
| Aug 27, 2015: Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield in GI ARS | 208 | 1 |
| Aug 21, 2015: New drug protects against the deadly effects of nuclear radiation 24 hours after exposure | 208 | 1 |
| Aug 18, 2015: Chrysalis BioTherapeutics' TP508 Reverses Radiation-Induced GI Damage | 209 | 2 |
| Appendix | 211 | 2 |
| Methodology | 211 | 1 |
| Coverage | 211 | 1 |
| Secondary Research | 211 | 1 |
| Primary Research | 211 | 1 |
| Expert Panel Validation | 211 | 1 |
| Contact Us | 211 | 1 |
| Disclaimer | 212 | 1 |
